Pasqal – Quantum Pioneer with Nobel Prize DNA After the Sell-Off: Speculative Opportunity for Patient Investors!

Support from Wall Street: On Friday, Cantor-Fitzgerald analyst Troy Jensen initiated coverage of Pasqal shares with a rating of "Overweight” and a price target of $12 – which represents over 130% upside potential from the current price of $5.12. This is beneficial for the stock, as it has lost around 80% since its SPAC debut at the end of August, when it briefly climbed to $24.68. A small issue: Cantor Fitzgerald was an advisor on the SPAC side during the IPO. Quantum computing remains one of the most exciting technology trends , but widespread...